From Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs:

Nura Bio CEO Alpna Seth

Nura Bio CEO Alpna Seth—

Headshot of Alpna Seth courtesy of Nura Bio

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX

Sponsored · Whitepaper
Bridging the Diversity Gap with Decentralized Trials
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!